Your browser is no longer supported. Please, upgrade your browser.
Settings
VECT [NASD]
VectivBio Holding AG
Index- P/E- EPS (ttm)- Insider Own8.88% Shs Outstand35.86M Perf Week-14.00%
Market Cap493.46M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.66M Perf Month-
Income- PEG- EPS next Q- Inst Own44.59% Short Float5.64% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.70 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.47 - 37.70 Perf YTD-43.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.50% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low-4.91% ATR2.05
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility5.75% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close14.48
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume377.57K Price13.76
Recom- SMA20-16.02% SMA50-16.02% SMA200-16.02% Volume54,154 Change-4.97%
May-04-21Initiated SVB Leerink Outperform $28
May-04-21Initiated Credit Suisse Outperform $24
May-04-21Initiated BofA Securities Buy $19
Apr-13-21 09:53PM  
08:06PM  
Apr-09-21 12:32PM  
Apr-08-21 10:27PM  
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.